Electra Therapeutics priced a $350 million Nasdaq IPO, joining a wave of large 2026 listings and signaling continued appetite for commercial-stage biotech funding. The proceeds are slated to support Electra’s shift toward commercialization as investors evaluate its pipeline and platform progress in a crowded market.